Alzheimer's Disease and other dementias affect over 50 million people worldwide. Early intervention is crucial. The sooner it's diagnosed, the better the disease's progression can be slowed, allowing for more time with an increased quality of life.
The Jacobs School of Medicine and Biomedical Sciences is among 72 sites nationwide that are recruiting patients for a 12-week, randomized, placebo-controlled drug trial for the first treatment designed to benefit patients with mild-to-moderate Lewy body dementia (LBD).
Bruce R. Troen, MD, professor of medicine and chief of the Division of Geriatrics and Palliative Medicine, was honored by the Amherst Senior Citizens Foundation (ASCF) with its Senior Leadership Award.
